Avalo Therapeutics (AVTX) Cost of Revenue (2017 - 2024)
Avalo Therapeutics (AVTX) posted Cost of Revenue of $714000.0 for Q3 2024, up 108.16% on a QoQ basis from $343000.0 in Q2 2024, and up 189.07% year-over-year from $247000.0 in Q4 2023.
Avalo Therapeutics (AVTX) Cost of Revenue (2017 - 2024) Analysis & Trends
Avalo Therapeutics' Cost of Revenue history runs 8 years deep, the most recent figure standing at $714000.0 for Q3 2024.
- Quarterly Cost of Revenue rose 189.07% year-over-year to $714000.0 in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $1.1 million (up 153.23% YoY) and the FY2023 annual result came in at $1.3 million, down 62.61% from the prior year.
- Cost of Revenue was $714000.0 for Q3 2024 at Avalo Therapeutics, up from $343000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $1.6 million in Q2 2022 and bottomed at -$221000.0 in Q4 2023.
- A 5-year average of $402578.9 and a median of $343000.0 in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 1787.95% — and 2023, when it slumped 135.65%.
- Avalo Therapeutics' Cost of Revenue stood at $79000.0 in 2020, then surged by 436.71% to $424000.0 in 2021, then surged by 46.23% to $620000.0 in 2022, then slumped by 135.65% to -$221000.0 in 2023, then jumped by 423.08% to $714000.0 in 2024.
- Business Quant data shows AVTX's Cost of Revenue at $714000.0 in Q3 2024, $343000.0 in Q2 2024, and $80000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Avalo Therapeutics | 395.30 Mn | 338.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 714,000.00 |
| Sep 30, 2024 | 714,000.00 |
| Jun 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 343,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | -221,000.00 |
| Dec 31, 2023 | -221,000.00 |
| Sep 30, 2023 | 247,000.00 |
| Sep 30, 2023 | 247,000.00 |
| Jun 30, 2023 | 708,000.00 |
| Jun 30, 2023 | 708,000.00 |
| Mar 31, 2023 | 551,000.00 |
| Mar 31, 2023 | 551,000.00 |
| Dec 31, 2022 | 620,000.00 |
| Dec 31, 2022 | 620,000.00 |
| Sep 30, 2022 | 528,000.00 |
| Sep 30, 2022 | 528,000.00 |
| Jun 30, 2022 | 1.57 Mn |
| Jun 30, 2022 | 1.57 Mn |